Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward

July 30, 2020

In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing will likely become a part of regular medical practice and represents an era of ‘personalized medicine’.  Costs associated with genomic screening will be substantial, including not only direct costs but also subsequent costs associated with diagnostic testing, treatment interventions and harms associated with screening and testing, although there are cost offsets and gains in economic productivity. Accrued savings are decades in the future.  However, while personalized medicine may be a key to population health, the way forward will be costly, wasteful, and potentially harmful without the establishment of priorities, adherence to rules of evidence, and the patience to wait for outcomes to unfold over years of observation.”

To read more, click here.

(Source:  JAMA, July 30, 2020)

Share This Story!